相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition
Mahesh Tambe et al.
LEUKEMIA (2020)
Bilirubin nanomedicine alleviates psoriatic skin inflammation by reducing oxidative stress and suppressing pathogenic signaling
Hyeongseop Keum et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H. Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia
Abhishek Maiti et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies
Boaz Mendzelevski et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Therapeutic strategies to target RAS-mutant cancers
Meagan B. Ryan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
Eliza Vakana et al.
ONCOTARGET (2017)
Autophagy is an important event for low-dose cytarabine treatment in acute myeloid leukemia cells
Liyun Chen et al.
LEUKEMIA RESEARCH (2017)
Emerging therapies for acute myeloid leukemia: translating biology into the clinic
Simon Kavanagh et al.
JCI INSIGHT (2017)
Molecular therapy for acute myeloid leukaemia
Catherine C. Coombs et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies
Gautam Borthakur et al.
CANCER (2016)
Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view
Shaoyong Lu et al.
CHEMICAL SOCIETY REVIEWS (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Inhibition of RAF lsoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Sheng-Bin Peng et al.
CANCER CELL (2015)
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors
Mark A. Dickson et al.
INVESTIGATIONAL NEW DRUGS (2015)
Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial
Nitin Jain et al.
CLINICAL CANCER RESEARCH (2014)
Isophilippinolide A Arrests Cell Cycle Progression and Induces Apoptosis for Anticancer Inhibitory Agents in Human Melanoma Cells
Hui-Min David Wang et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2014)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma
Roberta Schmieder et al.
NEOPLASIA (2013)
Targeting oncogenic Ras signaling in hematologic malignancies
Ashley F. Ward et al.
BLOOD (2012)
Clinical and Proteomic Characterization of Acute Myeloid Leukemia With Mutated RAS
Tapan M. Kadia et al.
CANCER (2012)
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
L. S. Steelman et al.
LEUKEMIA (2011)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
L. S. Steelman et al.
LEUKEMIA (2008)
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885
Alastair J. King et al.
CANCER RESEARCH (2006)
Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia
Steven M. Kornblau et al.
BLOOD (2006)
Targeting ras signalling pathways in cancer therapy
J Downward
NATURE REVIEWS CANCER (2003)
分享论文
